Assessment of antiproliferative potency of opioid peptide analogue biphalin in human glioblastoma cell line T98G

• Autorzy: Lazarczyk M. , Matyja E. , Lipkowski A.W.
• Języki publikacji: EN

Abstrakty

EN

Biphalin is a new type of opioid peptide analogue with high analgesic potency that is over 1000-fold greater than morphine, a well-known opiate compound widely utilized in pain management. Because of its less addictive nature than morphine, this substance has been suggested as an useful analgesic drug. Biphalinís high analgesic activity may be related with interaction with all three types of opioid receptors (mu, delta and kappa), belonging to G proteincoupled receptors (GPCR) family. These members of GPCR are expressed by astrocytes, including neoplastic glioma cells. It has been evidenced, that opioid receptors, particularly MOR (mu opioid receptor) and KOR (kappa opioid receptor) are involved in growth regulation of glioma cells. The alteration of tumor cell proliferation might be associated with adenylate cyclase inhibition, that results in decrease of intracellular cAMP level and prevention of PKA activation. The present study was performed on human glioblastoma cell line TG98 to establish the effect of biphalin on neoplastic cell growth and proliferation abilities. The glioma cell line exposed to biphalin at increasing concentrations exhibited the decrease of growth rate, reduction of cell ability to form colonies and alteration of Ki-67 proliferation index. These results suggest that this opioid peptide analogue is promising medicine in simultaneous analgesic and anti-cancer therapy. The work was supported by the Ministry of Science and Education, Grant No. NN401228334 and European Grant Normolife No. LSHC-CT-2006-037733.

• Wydawca: -
• Czasopismo: Acta Neurobiologiae Experimentalis
• Rocznik: 2009
• Tom: 69
• Numer: 1
• Opis fizyczny: p.85-86

Twórcy

autor

Lazarczyk M.

• Department of Experimental and Clinical Neuropathology, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland

autor

Matyja E.

• Department of Experimental and Clinical Neuropathology, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland

autor

Lipkowski A.W.

• Department of Neuropeptide, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland